EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Modifying inhibitor specificity for homologous enzymes by machine learning

Dor S Gozlan iD, Reut Meiri, Gili Shapira, Matt Coban, Evette S Radisky iD, Yaron Orenstein iD, Niv Papo iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70249 ↗

At a glance

Journal article in The FEBS Journal, 2026. Written by Dor S Gozlan and 6 co-authors. Institution: Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Major MEDLINE topics: Machine Learning, Matrix Metalloproteinase Inhibitors, Tissue Inhibitor of Metalloproteinase-2. 52 references. The full text is freely available (open access, CC BY 4.0). Funded by: United States-Israel Binational Science Foundation, Rosetrees Trust, Israel Cancer Research Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Selective inhibitors are essential for targeted therapeutics and for probing enzyme functions in various biological systems. The two main challenges in identifying such protein‐based inhibitors lie in the extensive experimental effort required, including the generation of large libraries, and in tailoring the selectivity of inhibitors to enzymes with homologous structures. To address these challenges, machine learning (ML) is being used to improve protein design by training on targeted libraries and identifying key interface mutations that enhance affinity and specificity. However, such ML‐based methods are limited by inaccurate energy calculations and difficulties in predicting the structural impacts of multiple mutations. Here, we present an ML‐based method that leverages HTS data to streamline the design of selective protease inhibitors. To demonstrate its utility, we applied our new method to find inhibitors of matrix metalloproteinases (MMPs), a family of homologous proteases involved in both physiological and pathological processes. By training ML models on binding data for three MMPs (MMP‐1, MMP‐3, and MMP‐9), we successfully designed a novel N‐TIMP2 variant with a differential specificity profile, namely, high affinity for MMP‐9, moderate affinity for MMP‐3, and low affinity for MMP‐1. Our experimental validation showed that this novel variant exhibited a significant specificity shift and enhanced selectivity compared with wild‐type N‐TIMP2. Through molecular modeling and energy minimization, we obtained structural insights into the variant's enhanced selectivity. Our findings highlight the power of ML‐based methods to reduce experimental workloads, facilitate the rational design of selective inhibitors, and advance the understanding of specific inhibitor–enzyme interactions in homologous enzyme systems.

Subjects

MeSH terms (MEDLINE)

Machine LearningMatrix Metalloproteinase InhibitorsTissue Inhibitor of Metalloproteinase-2HumansMatrix Metalloproteinase 9Matrix Metalloproteinase 3Matrix Metalloproteinase 1Protein BindingSubstrate SpecificityModels, MolecularMatrix Metalloproteinases

Author keywords

deep mutational scanningmatrix metalloproteinasesneural networksprotein engineeringprotein–protein interactions

Substances

Matrix Metalloproteinase InhibitorsTissue Inhibitor of Metalloproteinase-2Matrix Metalloproteinase 9TIMP2 protein, humanMatrix Metalloproteinase 3Matrix Metalloproteinase 1Matrix Metalloproteinases

Authors and institutions

  • Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Computer Science, Bar-Ilan University, Ramat Gan, Israel.
  • Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.
  • The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
  • National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

ORCID profiles: Dor S Gozlan, Evette S Radisky, Yaron Orenstein, Niv Papo

Funding

  • United States-Israel Binational Science Foundation
  • Rosetrees Trust
  • Israel Cancer Research Fund
  • Worldwide Cancer Research

Cite

APA

Gozlan, D. S., Meiri, R., Shapira, G., Coban, M., Radisky, E. S., Orenstein, Y., & Papo, N. (2026). Modifying inhibitor specificity for homologous enzymes by machine learning. The FEBS Journal. https://doi.org/10.1111/febs.70249

Vancouver

Gozlan DS, Meiri R, Shapira G, Coban M, Radisky ES, Orenstein Y, et al. Modifying inhibitor specificity for homologous enzymes by machine learning. The FEBS Journal. 2026. doi:10.1111/febs.70249

BibTeX
@article{Gozlan2026,
  author = {Gozlan, Dor S and Meiri, Reut and Shapira, Gili and Coban, Matt and Radisky, Evette S and Orenstein, Yaron and Papo, Niv},
  title = {Modifying inhibitor specificity for homologous enzymes by machine learning},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70249}
}
Start for free →